Gastrin Peptide Immunogenic Composition

Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.


Claims
Owners (US)
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jun 25, 2019
  • Application: May 16, 2014
    US US 201414892973 A
  • Priority: May 16, 2014
    EP EP 2014060088 W
  • Priority: May 21, 2013
    EP EP 13168565 A

Download Citation


Sign in to the Lens

Feedback